PRGO:NYE-Perrigo Company PLC (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 25.63

Change

+0.08 (+0.31)%

Market Cap

N/A

Volume

1.43M

Analyst Target

USD 57.88
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+3.34 (+1.74%)

USD 89.02B
HLN Haleon plc

N/A

USD 48.04B
TAK Takeda Pharmaceutical Co Ltd A..

+0.07 (+0.48%)

USD 47.42B
RDY Dr. Reddy’s Laboratories Ltd..

+0.42 (+0.53%)

USD 13.05B
CTLT Catalent Inc

+0.43 (+0.72%)

USD 10.91B
ELAN Elanco Animal Health

+0.07 (+0.51%)

USD 6.96B
BHC Bausch Health Companies Inc

+0.08 (+1.00%)

USD 2.98B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.01 (+0.12%)

USD 2.58B
CPHI China Pharma Holdings Inc

+0.03 (+12.55%)

USD 3.66M
YCBD cbdMD Inc

N/A

USD 1.73M

ETFs Containing PRGO

FLWR:SW 15.27 % 0.00 %

N/A

N/A
HLIT:CA Global X Lithium Producer.. 10.39 % 0.00 %

+0.94 (+5.75%)

CAD 0.03B
ION Proshares S&P Global Core.. 3.98 % 0.00 %

+1.55 (+5.75%)

USD 2.24M
WSRD:CA Wealthsimple Developed Ma.. 1.10 % 0.00 %

+0.67 (+5.75%)

CAD 0.70B
GNRX 0.00 % 0.55 %

N/A

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

+0.24 (+5.75%)

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

+0.44 (+5.75%)

N/A
ISRL:LSE 0.00 % 0.00 %

N/A

N/A
TASE:LSE 0.00 % 0.00 %

N/A

N/A
QDVM:F 0.00 % 0.00 %

N/A

N/A
QDVM:XETRA 0.00 % 0.00 %

N/A

N/A
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
BLUM:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -20.35% 20% F 9% A-
Dividend Return 1.72% 60% D- 37% F
Total Return -18.64% 20% F 9% A-
Trailing 12 Months  
Capital Gain -19.28% 20% F 10% F
Dividend Return 2.60% 80% B- 39% F
Total Return -16.68% 20% F 10% F
Trailing 5 Years  
Capital Gain -53.38% 38% F 8% B-
Dividend Return 8.65% 50% F 30% F
Total Return -44.74% 43% F 9% A-
Average Annual (5 Year Horizon)  
Capital Gain -13.01% 25% F 6% D-
Dividend Return -10.65% 25% F 6% D-
Total Return 2.37% 83% B 51% F
Risk Return Profile  
Volatility (Standard Deviation) 8.11% 100% F 82% B
Risk Adjusted Return -131.33% 6% D- N/A F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector